rocakinogene sifuplasmid
rocakinogene sifuplasmid: 4 clinical trials tracked.
rocakinogene sifuplasmid evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about rocakinogene sifuplasmid, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (4)
Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations
Primary endpoint: Dose Limiting Toxicities
An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) Treatment
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Primary endpoint: Percentage of Participants with Adverse Events (AEs)
Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection
Primary endpoint: Incidence of dose-limiting toxicity